Literature DB >> 21769642

Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.

Hideaki Kabuto1, Tomoko T Yamanushi.   

Abstract

Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the nigrostriatal system and dopamine (DA) depletion in the striatum. The most popular therapeutic medicine for treating PD, 3-(3,4-Dihydroxyphenyl)-L-alanine (L-DOPA), has adverse effects, such as dyskinesia and disease acceleration. As superoxideO(2)(-)) and hydroxyl radical (·OH) have been implicated in the pathogenesis of PD, free radical scavenging and antioxidants have attracted attention as agents to prevent disease progression. Rodents injected with 6-hydroxydopamine (6-OHDA) intracerebroventricularly are considered to be a good animal model of PD. Zingerone and eugenol, essential oils extracted from ginger and cloves, are known to have free radical scavenging and antioxidant effects. Therefore, we examined the effects of zingerone and eugenol on the behavioral problems in mouse model and on the DA concentration and antioxidant activities in the striatum after 6-OHDA administration and L-DOPA treatment. Daily oral administration of eugenol/zingerone and injection of L-DOPA intraperitoneally for 4 weeks following a single 6-OHDA injection did not improve abnormal behaviors induced by L-DOPA treatment. 6-OHDA reduced the DA level in the striatum; surprisingly, zingerone and eugenol enhanced the reduction of striatal DA and its metabolites. Zingerone decreased catalase activity, and increased glutathione peroxidase activity and the oxidized L-ascorbate level in the striatum. We previously reported that pre-treatment with zingerone or eugenol prevents 6-OHDA-induced DA depression by preventing lipid peroxidation. However, the present study shows that post-treatment with these substances enhanced the DA decrease. These substances had adverse effects dependent on the time of administration relative to model PD onset. These results suggest that we should be wary of ingesting these spice elements after the onset of PD symptoms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769642     DOI: 10.1007/s11064-011-0548-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  30 in total

Review 1.  Oxygen free radicals and Parkinson's disease.

Authors:  J D Adams; I N Odunze
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

2.  EPC-K1, a hydroxyl radical scavenger, prevents 6-hydroxydopamine-induced dopamine depletion in the mouse striatum by up-regulation of catalase activity.

Authors:  H Kabuto; I Yokoi; E Iwata-Ichikawa; N Ogawa
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

Review 3.  Parkinson's disease and free radicals. Mechanism of neurodegeneration and neuroprotection.

Authors:  T Kondo
Journal:  Ann N Y Acad Sci       Date:  1996-06-15       Impact factor: 5.691

4.  Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes.

Authors:  A C Reddy; B R Lokesh
Journal:  Mol Cell Biochem       Date:  1992-04       Impact factor: 3.396

5.  Antioxidant action of eugenol compounds: role of metal ion in the inhibition of lipid peroxidation.

Authors:  Masae Ito; Keiko Murakami; Masataka Yoshino
Journal:  Food Chem Toxicol       Date:  2005-03       Impact factor: 6.023

6.  Eugenol [2-methoxy-4-(2-propenyl)phenol] prevents 6-hydroxydopamine-induced dopamine depression and lipid peroxidation inductivity in mouse striatum.

Authors:  Hideaki Kabuto; Mika Tada; Masahiro Kohno
Journal:  Biol Pharm Bull       Date:  2007-03       Impact factor: 2.233

7.  Brain peroxidase and catalase in Parkinson disease.

Authors:  L M Ambani; M H Van Woert; S Murphy
Journal:  Arch Neurol       Date:  1975-02

8.  Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.

Authors:  D T Dexter; F R Wells; A J Lees; F Agid; Y Agid; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1989-06       Impact factor: 5.372

9.  Free radical-generated neurotoxicity of 6-hydroxydopamine.

Authors:  R Kumar; A K Agarwal; P K Seth
Journal:  J Neurochem       Date:  1995-04       Impact factor: 5.372

10.  Inhibitory effect of eugenol on non-enzymatic lipid peroxidation in rat liver mitochondria.

Authors:  E Nagababu; N Lakshmaiah
Journal:  Biochem Pharmacol       Date:  1992-06-09       Impact factor: 5.858

View more
  10 in total

Review 1.  Pharmacological and Toxicological Properties of Eugenol.

Authors:  Solmaz Mohammadi Nejad; Hilal Özgüneş; Nursen Başaran
Journal:  Turk J Pharm Sci       Date:  2017-08-15

Review 2.  Essential Oils as a Potential Neuroprotective Remedy for Age-Related Neurodegenerative Diseases: A Review.

Authors:  Aswir Abd Rashed; Ahmad Zuhairi Abd Rahman; Devi Nair Gunasegavan Rathi
Journal:  Molecules       Date:  2021-02-19       Impact factor: 4.411

Review 3.  A review: traditional herbs and remedies impacting pathogenesis of Parkinson's disease.

Authors:  Vishavdeep Sharma; Onkar Bedi; Manisha Gupta; Rahul Deshmukh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-08       Impact factor: 3.000

4.  Heated Leaf Extract of Coriandrum sativum L. Protects Nigral Dopaminergic Degeneration in Rats.

Authors:  Nana Saeki; Haruna Tamano; Azusa Takeuchi; Misa Katahira; Ryusuke Nishio; Haruna Tamura; Atsushi Takeda
Journal:  Plant Foods Hum Nutr       Date:  2022-08-03       Impact factor: 4.124

Review 5.  Elucidating the Beneficial Effects of Ginger (Zingiber officinale Roscoe) in Parkinson's Disease.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Sokratis G Papageorgiou; Christina Piperi
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-07

Review 6.  A Review on Pharmacological Properties of Zingerone (4-(4-Hydroxy-3-methoxyphenyl)-2-butanone).

Authors:  Bilal Ahmad; Muneeb U Rehman; Insha Amin; Ahmad Arif; Saiema Rasool; Showkat Ahmad Bhat; Insha Afzal; Ishraq Hussain; Sheikh Bilal; Manzoor ur Rahman Mir
Journal:  ScientificWorldJournal       Date:  2015-05-27

7.  Neuroprotective effect of pseudoginsenoside-f11 on a rat model of Parkinson's disease induced by 6-hydroxydopamine.

Authors:  Jian Yu Wang; Jing Yu Yang; Fang Wang; Shi Yuan Fu; Yue Hou; Bo Jiang; Jie Ma; Cui Song; Chun Fu Wu
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-10       Impact factor: 2.629

8.  Preconditioning of Adipose-Derived Mesenchymal Stem-Like Cells with Eugenol Potentiates Their Migration and Proliferation In Vitro and Therapeutic Abilities in Rat Hepatic Fibrosis.

Authors:  Moustafa Fathy; Motonori Okabe; Eman M Othman; Heba M Saad Eldien; Toshiko Yoshida
Journal:  Molecules       Date:  2020-04-26       Impact factor: 4.411

Review 9.  Eugenol--from the remote Maluku Islands to the international market place: a review of a remarkable and versatile molecule.

Authors:  Guy P Kamatou; Ilze Vermaak; Alvaro M Viljoen
Journal:  Molecules       Date:  2012-06-06       Impact factor: 4.411

10.  Effects of Combined Treatment with Acupuncture and Chunggan Formula in a Mouse Model of Parkinson's Disease.

Authors:  Tae-Yeon Hwang; Min-A Song; Sora Ahn; Ju-Young Oh; Dong-Hee Kim; Quan Feng Liu; Wonwoong Lee; Jongki Hong; Songhee Jeon; Hi-Joon Park
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-21       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.